See more : Canntab Therapeutics Limited (CTABF) Income Statement Analysis – Financial Results
Complete financial analysis of Arcellx, Inc. (ACLX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Arcellx, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- H.I.G. Acquisition Corp. (HIGA-WT) Income Statement Analysis – Financial Results
- ARIAKE JAPAN Co., Ltd. (2815.T) Income Statement Analysis – Financial Results
- Hankook & Company Co., Ltd. (000240.KS) Income Statement Analysis – Financial Results
- ABM International Limited (ABMINTLLTD.NS) Income Statement Analysis – Financial Results
- FirstGroup plc (FGP.L) Income Statement Analysis – Financial Results
Arcellx, Inc. (ACLX)
About Arcellx, Inc.
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 110.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 2.22M | 1.04M | 629.00K | 326.00K | 0.00 |
| Gross Profit | 110.32M | -2.22M | -1.04M | -629.00K | -326.00K | 0.00 |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 133.85M | 149.56M | 46.88M | 25.06M | 15.77M | 6.11M |
| General & Administrative | 66.35M | 41.70M | 18.14M | 7.04M | 2.21M | 2.20M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 66.35M | 41.70M | 18.14M | 7.04M | 2.21M | 2.20M |
| Other Expenses | 0.00 | 0.00 | 49.00K | 1.00K | 2.00K | 0.00 |
| Operating Expenses | 200.20M | 191.26M | 65.02M | 32.10M | 17.97M | 8.31M |
| Cost & Expenses | 200.20M | 191.26M | 65.02M | 32.10M | 17.97M | 8.31M |
| Interest Income | 23.70M | 4.30M | 300.00K | 1.00K | 0.00 | 0.00 |
| Interest Expense | 3.84M | 1.72M | 10.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.04M | 2.22M | 1.04M | 629.00K | 326.00K | 93.00K |
| EBITDA | -64.15M | -184.74M | -63.93M | -31.47M | -17.65M | -8.22M |
| EBITDA Ratio | -58.15% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -89.88M | -191.26M | -65.02M | -32.10M | -17.97M | -8.31M |
| Operating Income Ratio | -81.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 19.85M | 2.58M | 49.00K | 1.00K | 2.00K | 999.00 |
| Income Before Tax | -70.03M | -188.68M | -64.97M | -32.10M | -17.97M | -8.31M |
| Income Before Tax Ratio | -63.48% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 663.00K | -2.58M | -1.04M | 422.70K | 154.14K | 0.00 |
| Net Income | -70.69M | -186.10M | -63.93M | -32.10M | -17.97M | -8.31M |
| Net Income Ratio | -64.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.47 | -4.22 | -1.79 | -0.96 | -0.52 | -50.17 |
| EPS Diluted | -1.47 | -4.22 | -1.79 | -0.96 | -0.52 | -50.17 |
| Weighted Avg Shares Out | 48.06M | 44.11M | 35.74M | 33.54M | 34.78M | 165.58K |
| Weighted Avg Shares Out (Dil) | 48.06M | 44.11M | 35.74M | 33.54M | 34.78M | 165.58K |
Arcellx: Navigating The CAR T-Cell Revolution
Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market
Pharma's Frontline: 3 Stocks Driving Revolutionary Drug Development
Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH
3 Biotech Stocks That Could Be Multibaggers in the Making
Arcellx (ACLX) Up 5% on Partnership Expansion With Gilead
Arcellx: A Strong Contender In The CAR-T Multiple Myeloma Market
Arcellx stock climbs on Gilead investment
Arcellx's stock set to surge after Gilead makes $200 million investment at a 30% premium
Kite and Arcellx Announce Expansion in Strategic Partnership
Source: https://incomestatements.info
Category: Stock Reports